Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm

Contraception

Volumn 89, Issue 1, 2014, Pages 31-35

  Halpern, Vera ^a   Combes, Stephanie L ^a   Dorflinger, Laneta J ^a   Weiner, Debra H ^a   Archer, David F ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Contraception; Depot medroxyprogesterone acetate; Pharmacokinetics; Subcutaneous

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DEVELOPING COUNTRY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MAXIMUM PLASMA CONCENTRATION; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION;

CONTRACEPTION; DEPOT MEDROXYPROGESTERONE ACETATE; PHARMACOKINETICS; SUBCUTANEOUS;

ADULT; ARM; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; INJECTIONS; MEDROXYPROGESTERONE ACETATE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84889082434     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2013.07.002     Document Type: Article

References (25)

1. J. Jain, A.J. Jakimiuk, F.R. Bode, D. Ross, and A.M. Kaunitz Contraceptive efficacy and safety of DMPA-SC Contraception 70 2004 269 275
2. PATH. Injectable contraceptives in Uniject: fact sheet 2009.
3. V.D. Tsu, A. Sutanto, K. Vaidya, P. Coffey, and A. Widjaya Oxytocin in prefilled Uniject injection devices for managing third-stage labor in Indonesia Int J Gynaecol Obstet 83 2003 103 111
4. R. Quiroga, P. Halkyer, F. Gil, C. Nelson, and D. Kristensen A prefilled injection device for outreach tetanus immunization by Bolivian traditional birth attendants Rev Panam Salud Publica 4 1998 20 25
5. Depo-SubQ Provera 104™ (medroxyprogesterone acetate injectable suspension 104 mg/0.65 ml). Physician information. http://labeling.pfizer.com/ ShowLabeling.aspx?id=549. (Accessed May 01, 2013).
6. C. Binder, T. Lauritzen, O. Faber, and S. Pramming Insulin pharmacokinetics Diabetes Care 7 1984 188 199
7. T. Laursen, J.O. Jorgensen, and J.S. Christiansen Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen Clin Endocrinol 40 1994 373 378
8. Z. Xu, Q. Wang, and Y. Zhuang Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects J Clin Pharmacol 50 2010 276 284
9. S. Fishbane, A. Pannier, X. Liogier, P. Jordan, F.C. Dougherty, and B. Reigner Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration J Clin Pharmacol 47 2007 1390 1397
10. U.S. Food and Drug Administration. Depo-SubQ Provera 104 (medroxyprogesterone acetate) injectable suspension NDA no.: 21583. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/021583s000-ClinPharmR. pdf. (Accessed May 1, 2013)
11. J. Jain, C. Dutton, A. Nicosia, C. Wajszczuk, F.R. Bode, and D.R.J. Mishell Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera Contraception 70 2004 11 18
12. Y.C. Toh, J. Jain, M.H. Rahnny, F.R. Bode, and D. Ross Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women Clin Ther 26 2004 1845 1854
13. P. Segall-Gutierrez, D. Taylor, X. Liu, F. Stanzcyk, S. Azen, and D.R. Mishell Jr. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously Contraception 81 2010 487 495
14. M.H. Rahimy, K.K. Ryan, and N.K. Hopkins Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women Contraception 60 1999 209 214
15. D.R. Mishell Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception J Reprod Med 41 1996 381 390
16. T. Pardthaisong Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis J Biosoc Sci 16 1984 23 34
17. J. Garza-Flores, S. Cardenas, V. Rodriguez, M.C. Cravioto, V. Diaz-Sanchez, and G. Perez-Palacios Return to ovulation following the use of long-acting injectable contraceptives: a comparative study Contraception 31 1985 361 366
18. U.S. Food and Drug Administration. SBA for NDA 20-246: Depo-Provera C-150; pharmacokinetics review, pharmacokinetics update. 1999.
19. J.G. Flores, and T. Navarrete Pharmacokinetics of injectable contraceptives Gynaecol Forum 5 2000 7 10
20. S. Bassol, J. Garza-Flores, and M.C. Cravioto Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses Fertil Steril 42 1984 216 222
21. A.M. Kaunitz, P.D. Darney, D. Ross, K.D. Wolter, and L. Speroff Subcutaneous DMPA, vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density Contraception 80 2009 7 17
22. S. Said, K. Omar, and S. Koetsawang A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction Contraception 35 1987 591 610
23. V. Brache, P.D. Blumenthal, F. Alvarez, T.R. Dunson, L. Cochon, and A. Faundes Timing of onset of contraceptive effectiveness in Norplant implant users II. Effect on the ovarian function in the first cycle of use Contraception 59 1999 245 251
24. WHO Selected practice recommendations for contraceptive use, update 2008 2008 World Health Organization Geneva
25. U.S. Food and Drug Administration. Medroxyprogesterone acetate injectable suspension, 150 mg/mL prefilled syringe ANDA no.: 76-553. Center for Drug Evaluation and Research. Bioequivalence review. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2004/076553-S000-Medroxyprogesterone-BIOPHARMR.pdf. (Accessed May 01, 2013)